Key result
cPLA2α disruption in mice cuts infarct size ~47% and preserves LV function after ischemia-reperfusion.
Why the study?
Group IVA cytosolic phospholipase A2 (cPLA2α) plays a role in myocardial ischemia-reperfusion injury and its mechanistic link with TNF-α-mediated pathways is unclear.
Effect estimate: 47% decrease in myocardial infarct size
Absolute Event Rate: 21% vs 14%
Disruption of cPLA2α attenuates myocardial ischemia-reperfusion injury, partly through the inhibition of TNF-α-mediated pathways.
cPLA2α disruption attenuates murine I/R injury via TNF-α pathways; leaves open translation to human cardioprotection.
Group IVA cytosolic phospholipase A(2) (cPLA(2)α), which preferentially cleaves arachidonic acid from phospholipids, plays a role in apoptosis and tissue injury. Downstream signals in response to tumor necrosis factor (TNF)-α, a mediator of myocardial ischemia-reperfusion (I/R) injury, involve cPLA(2)α activation. This study examined the potential role of cPLA(2)α and its mechanistic link with TNF-α in myocardial I/R injury using cPLA(2)α knockout (cPLA(2)α(-/-)) mice. Myocardial I/R was created with 10-wk-old male mice by 1 h ligation of the left anterior descending coronary artery, followed by 24 h of reperfusion. As a result, compared with wild-type (cPLA(2)α(+/+)) mice, cPLA(2)α(-/-) mice had a 47% decrease in myocardial infarct size, preservation of echocardiographic left ventricle (LV) function (%fractional shortening: 14 vs. 21%, respectively), and lower content of leukotriene B(4) and thromboxane B(2) (62 and 50% lower, respectively) in the ischemic myocardium after I/R. Treatment with the TNF-α inhibitor (soluble TNF receptor II/IgG1 Fc fusion protein, sTNFR:Fc) decreased myocardial I/R injury and LV dysfunction in cPLA(2)α(+/+) mice but not cPLA(2)α(-/-) mice. sTNFR:Fc also suppressed cPLA(2)α phosphorylation in the ischemic myocardium after I/R of cPLA(2)α(+/+) mice. Similarly, sTNFR:Fc exerted protective effects against hypoxia-reoxygenation (H/R)-induced injury in the cultured cardiomyocytes from cPLA(2)α(+/+) mice but not cPLA(2)α(-/-) cardiomyocytes. H/R and TNF-α induced cPLA(2)α phosphorylation in cPLA(2)α(+/+) cardiomyocytes, which was reversible by sTNFR:Fc. In cPLA(2)α(-/-) cardiomyocytes, TNF-α induced apoptosis and release of arachidonic acid to a lesser extent than in cPLA(2)α(+/+) cardiomyocytes. In conclusion, disruption of cPLA(2)α attenuates myocardial I/R injury partly through inhibition of TNF-α-mediated pathways.
No takes yet. Share an insight, caveat, or question.
Saitō et al. (2012) studied Myocardial ischemia-reperfusion injury. cPLA(2)α knockout vs. Wild-type (cPLA(2)α(+/+)) mice was evaluated on Echocardiographic left ventricle function (% fractional shortening) (47% decrease in myocardial infarct size). Disruption of cPLA(2)α in mice decreased myocardial infarct size by 47% and preserved left ventricular fractional shortening (21% vs 14%) after ischemia-reperfusion injury compared to wild-type mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: